0001213900-26-048608
SEC filingSeaStar Medical is a commercial-stage healthcare company offering its SCD therapy for hyperinflammation, with this S-1 registering 1,664,543 shares for resale by Lincoln Park under a $15.0 million purchase agreement.
SeaStar Medical is a commercial-stage healthcare company that has received FDA approval under a Humanitarian Device Exemption for its pediatric SCD therapy (QUELIMMUNE) for acute kidney injury due to sepsis. The company is also conducting a pivotal adult trial (NEUTRALIZE-AKI) and a feasibility study for cardiorenal syndrome. The SCD therapy has six Breakthrough Device Designations, indicating a potentially expedited regulatory pathway for additional indications. The company estimates a market of over one million patients annually with hyperinflammatory conditions.
Financially, the company is not yet profitable and has relied on equity financings, including an at-the-market offering in 2025 that raised approximately $5.9 million. As of December 31, 2025, net tangible book value was $2.71 per share. The offering involves the resale of up to 1,664,543 shares by Lincoln Park Capital Fund, LLC under a purchase agreement that allows SeaStar to sell up to $15.0 million of common stock over 36 months. The company will not receive proceeds from the resale but may receive up to $14.66 million from future sales to Lincoln Park. The purchase price is set at a discount to market, which could result in significant dilution. Assuming a purchase price of $4.63 per share, the offering would result in dilution of $1.34 per share to new investors.
Key risks include the dilutive nature of the Lincoln Park arrangement, the unpredictability of proceeds, and the need for substantial additional capital. The company has a history of operating losses and expects to continue incurring losses. A shareholder class action was dismissed with prejudice in April 2026, and a derivative action is stayed. Management has broad discretion over the use of any proceeds, which are intended for working capital and general corporate purposes.
The management team includes CEO Eric Schlorff, who has a background at Dow Chemical, and CFO Michael Messinger, who has experience in biotech financing. The board is classified with staggered terms, which may have anti-takeover effects. Overall, this filing is material due to the potential for significant dilution and the company's reliance on the Lincoln Park facility for funding.